Literature DB >> 402473

A new polyvalent Pseudomonas vaccine.

J M Miler, J F Spilsbury, R J Jones, E A Roe, E J Lowbury.   

Abstract

This paper describes the preparation, chemical characterisation and immunogenic properties of a new polyvalent pseudomonas vaccine. New cultural methods were devised which allowed a build-up of the immunogen in the cell wall of the bacteria, and mild extraction techniques were used to remove the immunogens from the cell wall of living bacteria without apparent physical or chemical change which might affect immunogenicity. The polyvalent vaccine comprised 16 component vaccines, each a lipid-protein-carbohydrate complex extracted from one of the 16 different serotypes of Pseudomonas aeruginosa. Single injections into mice of each of the 16 component vaccines induced protection against several strains of homologous serotypes within 3 days of vaccination. The polyvalent vaccine induced similar protection against several strains of each of the 16 serotypes. We would like to thank R. E. Dyster, K. Digby and J. Simmonds for their technical assistance.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402473     DOI: 10.1099/00222615-10-1-19

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  23 in total

1.  Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.

Authors:  R J Jones
Journal:  J Hyg (Lond)       Date:  1979-06

2.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

3.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

4.  Immunogenic properties of Klebsiella pneumoniae type 2 capsular polysaccharide.

Authors:  A Robert; H Jouin; J M Fournier
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

5.  Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; R Lucken; P Owen
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

Review 6.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  The NBT test in burned patients.

Authors:  E A Roe; R J Jones
Journal:  Br J Exp Pathol       Date:  1979-04

8.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

Review 9.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

10.  Temperature-sensitive mutants of Pseudomonas aeruginosa: isolation and preliminary immunological evaluation.

Authors:  A M Hooke; P J Arroyo; M P Oeschger; J A Bellanti
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.